Search

Your search keyword '"Cai, Yiying"' showing total 8 results
Start Over Author "Cai, Yiying" Publisher american society for microbiology
8 results on '"Cai, Yiying"'

2. Determining the Development of Persisters in Extensively Drug-Resistant Acinetobacter baumannii upon Exposure to Polymyxin B-Based Antibiotic Combinations Using Flow Cytometry

Author

Wong, Fiona Hui-Sian, primary, Cai, Yiying, additional, Leck, Hui, additional, Lim, Tze-Peng, additional, Teo, Jocelyn Qi-Min, additional, Lee, Winnie, additional, Koh, Tse Hsien, additional, Tan, Thuan Tong, additional, Tan, Kar Wai, additional, and Kwa, Andrea Lay-Hoon, additional

Published
2020
Full Text
View/download PDF

4. Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model

Author

Cai, Yiying, primary, Lim, Tze-Peng, additional, Teo, Jocelyn Qi-Min, additional, Sasikala, Suranthran, additional, Chan, Eric Chun Yong, additional, Hong, Yan Jun, additional, Lee, Winnie, additional, Tan, Thean Yen, additional, Tan, Thuan Tong, additional, Koh, Tse Hsien, additional, Hsu, Li Yang, additional, and Kwa, Andrea L., additional

Published
2017
Full Text
View/download PDF

5. In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B

Author

Cai, Yiying, primary, Lim, Tze-Peng, additional, Teo, Jocelyn, additional, Sasikala, Suranthran, additional, Lee, Winnie, additional, Hong, Yanjun, additional, Chan, Eric Chun Yong, additional, Tan, Thean Yen, additional, Tan, Thuan-Tong, additional, Koh, Tse Hsien, additional, Hsu, Li Yang, additional, and Kwa, Andrea L., additional

Published
2016
Full Text
View/download PDF

6. Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections

Author

Cai, Bingxuan, primary, Cai, Yiying, additional, Liew, Yi Xin, additional, Chua, Nathalie Grace, additional, Teo, Jocelyn Qi-Min, additional, Lim, Tze-Peng, additional, Kurup, Asok, additional, Ee, Pui Lai Rachel, additional, Tan, Thuan Tong, additional, Lee, Winnie, additional, and Kwa, Andrea Lay-Hoon, additional

Published
2016
Full Text
View/download PDF

7. In Vitro Pharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant Klebsiella pneumoniae

Author

Lim, Tze-Peng, primary, Cai, Yiying, additional, Hong, Yanjun, additional, Chan, Eric Chun Yong, additional, Suranthran, Sasikala, additional, Teo, Jocelyn Qi-Min, additional, Lee, Winnie Huiling, additional, Tan, Thean-Yen, additional, Hsu, Li-Yang, additional, Koh, Tse-Hsien, additional, Tan, Thuan-Tong, additional, and Kwa, Andrea Lay-Hoon, additional

Published
2015
Full Text
View/download PDF

8. Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model.

Author

Cai Y, Lim TP, Teo JQ, Sasikala S, Chan EC, Hong YJ, Lee W, Tan TY, Tan TT, Koh TH, Hsu LY, and Kwa AL

Subjects
Drug Resistance, Bacterial genetics, Escherichia coli enzymology, Microbial Sensitivity Tests, Minocycline analogs & derivatives, Minocycline pharmacology, Tigecycline, Anti-Bacterial Agents pharmacology, Carbapenems pharmacology, Escherichia coli drug effects, Polymyxin B pharmacology
Abstract

Polymyxin B-based combinations have emerged as a mainstay treatment against carbapenem-resistant Escherichia coli (CREC). We investigated the activity of polymyxin B-based two-antibiotic combinations against CREC using time-kill studies (TKS) and validated the findings in a hollow-fiber infection model (HFIM). TKS were conducted using 5 clinical CREC strains at 5 log 10 CFU/ml against 10 polymyxin B-based two-antibiotic combinations at maximum clinically achievable concentrations. HFIMs simulating dosing regimens with polymyxin B (30,000U/kg/day) and tigecycline (100 mg every 12 h) alone and in combination were conducted against two CREC strains at 5 log 10 CFU/ml over 120 h. Emergence of resistance was quantified using antibiotic-containing media. Phenotypic characterization (growth rate and stability of resistant phenotypes) of the resistant isolates was performed. All five CREC strains harbored carbapenemases. Polymyxin B and tigecycline MICs ranged from 0.5 mg/liter to 2 mg/liter and from 0.25 mg/liter to 8 mg/liter, respectively. All antibiotics alone did not have bactericidal activity at 24 h in the TKS, except for polymyxin B against two strains. In combination TKS, only polymyxin B plus tigecycline demonstrated both bactericidal activity and synergy in two out of five strains. In the HFIM, polymyxin B alone was bactericidal against both CREC strains before regrowth was observed at 8 h. Phenotypically stable polymyxin B-resistant mutants were observed for both strains, with a reduced growth rate observed in one strain. Tigecycline alone resulted in a slow reduction in bacterial counts. Polymyxin B plus tigecycline resulted in rapid and sustained bactericidal killing up to 120 h. Polymyxin B plus tigecycline is a promising combination against CREC. The clinical relevance of our results warrants further investigations., (Copyright © 2016 American Society for Microbiology.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results